BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) finished Wednesday with a subtraction of -$0.13 to close at $7.12, a downside of -1.79 percent. An average of 2,567,300 shares of common stock have been traded in the last five days. There was a gain of $0.20 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 3,041,070 shares traded, while the 50-day average volume stands at 2,729,392.
BCRX stock has decreased by -6.81% in the last month. The company shares reached their 1-month lowest point of $6.62 on 08/08/23. With the stock rallying to its 52-week high on 01/06/23, shares of the company touched a low of $6.62 and a high of $15.12 in 52 weeks. It has reached a new high 3 times so far this year and lost -37.98% or -$4.36 in price. In spite of this, the price is down -52.91% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
BCRX stock investors should be aware that BioCryst Pharmaceuticals Inc. (BCRX) stock had its last reported insider trading activity 70 days ago on Jun 15. In this transaction, the insider spent $31,920. Director, Hutson Nancy J, disposed of 12,866 shares at a price of $8.04 on Jun 14. The insider now owns more than $103,443 worth of shares. Prior to that, Chief R&D Officer Thackray Helen M. went on to Sale 7,000 shares at $8.29 each on Apr 03. An amount of $58,030 was transacted.
Valuation Metrics
BioCryst Pharmaceuticals Inc. (BCRX) stock’s beta is 1.86. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.33.
Financial Health
The quick ratio of BioCryst Pharmaceuticals Inc. for the three months ended June 29 was 5.20, and the current ratio was 5.50, indicating that the company is able to meet its debt obligations. BioCryst Pharmaceuticals Inc.’s EBITDA margin for the year ending June 29 is -54.28%, while its operating margin for the same period stands at -46.30%. Its gross profit as reported stood at $264.42 million compared to revenue of $270.83 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, BioCryst Pharmaceuticals Inc.’s return on assets was -45.20%.
Earnings Surprise
For the three-month period that ended June 29, BioCryst Pharmaceuticals Inc. had $293.18 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$75.33 million in the quarter, while revenues of -$53.33 million were grew 21.86%. The analyst consensus anticipated BioCryst Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.23 per share, but it turned out to be -$0.4, a -73.90% surprise. For the quarter, EBITDA amounted to -$23.13 million. Shareholders own equity worth $189.49 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at BioCryst Pharmaceuticals Inc. (BCRX) price momentum. RSI 9-day as of the close on 23 August was 48.74%, suggesting the stock is Neutral, with historical volatility in this time frame at 42.42%.
As of today, BCRX’s price is $7.20 +2.89% or $0.20 from its 5-day moving average. BCRX is currently trading -10.10% lower than its 20-day SMA and -15.14% lower than its 100-day SMA. However, the stock’s current price level is -14.22% below the SMA50 and -40.81% below the SMA200.
The stochastic %K and %D were 53.87% and 51.64%, respectively, and the average true range (ATR) was 0.36. With the 14-day stochastic at 40.00% and the average true range at 0.36, the RSI (14) stands at 48.36%. The stock has reached 0.19 on the 9-day MACD Oscillator while the 14-day reading was at 0.20.
Analyst Ratings
Jefferies upgraded BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold.
What is BCRX’s price target for the next 12 months?
Analysts predict a range of price targets between $8.00 and $30.00, with a median target of $11.50. Taking a look at these predictions, the average price target given by analysts for BioCryst Pharmaceuticals Inc. (BCRX) stock is $15.10.
